UK markets closed

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0400+0.5500 (+22.09%)
At close: 2:05PM BST

Transgene SA

400, Boulevard Gonthier d’Andernach
Parc d’Innovation – CS80166 Cedex
Illkirch-Graffenstaden 67405
France
33 3 88 27 91 00
http://www.transgene.fr

Sector(s)
Industry
Full-time employees139

Key executives

NameTitlePayExercisedYear born
Mr. Hedi Ben BrahimChairman & CEON/AN/A1982
Mr. Jean-Philippe DelVP & CFON/AN/A1981
Dr. Éric QuéméneurExec. VP & Chief Scientific OfficerN/AN/A1965
Ms. Elisabetta CastelliDirector of Investor RelationsN/AN/AN/A
Mr. John FelittiVP, Gen. Counsel & Corp. Sec.N/AN/A1970
Lucie LarguierDirector of Corp. Communications & IRN/AN/AN/A
Mr. Thibaut du FayetVP of Corp. Devel.N/AN/A1968
Ms. Gaelle StadtlerVP & Director of HRN/AN/AN/A
Mr. Philippe SlosHead of Preclinical Regulatory LaboratoryN/AN/AN/A
Dr. Maud Brandely-TalbotVP of Medical Affairs & Chief Medical OfficerN/AN/A1955
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Corporate governance

Transgene SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.